Abstract
Objective:To evaluate the safety and efficacy of neoadjuvant chemotherapy(NCT)in mid-low locally advanced rectal cancer with negative mesorectal fascia(MRF).Methods:This prospective,single-arm phase Ⅱ trial was designed and conducted at Peking University Cancer Hospital.The patients who provided consent received 3 months of NCT(capecitabine and oxaliplatin,CapOX)followed by total mesorectal excision(TME).The primary endpoint was the rate of pathological complete response(pCR).Results:From January 2019 through December 2021,a total of 53 patients were enrolled,7.5％of whom experienced grade 3-4 adverse events during NCT.The pCR rate was 17.0％for the entire cohort,and the overall rate of postoperative complications was 37.7％(1.9％of grade Ⅲa patients).The 3-year disease-free survival rate was 91.4％,and 23.5％(12/51)of the patients suffered from major low anterior resection syndrome(LARS).Postoperative complications were independently associated with major LARS.Conclusions:For patients with mid-low rectal cancer with negative MRF,3 months of NCT were found to yield a favorable tumor response with acceptable toxicity.With fair long-term survival,the NCT regimen could be associated with low rates of perioperative complications as well as acceptable anal function.
基金项目
Beijing Municipal Administration of Hospitals Incubating Program(PZ2020027)
Beijing Talent Incubating Funding(2019-4)
National Natural Science Foundation of China(81773214)
Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support(ZYLX202116)
2019 Major and Difficult Diseases Chinese and Western Medicine Coordination Capacity Colorectal Cancer Project(2018275)
Science Foundation of Peking University Cancer Hospital-2023(JC202310)
NETL
NSTL
万方数据